Boston Scientific Corporation stock research
FY2026 Q1
Boston Scientific (BSX) Gross Margin & Quarterly History
Explore Boston Scientific Corporation (BSX) gross margin from 2023 through the latest reported quarter, using SEC-sourced revenue, gross profit, and direct costs.
Gross margin takeaway
Quarter ended Mar 31, 2026 · FY2026 Q1
Revenue declined slightly compared to the prior quarter, while gross profit fell in proportion, leaving gross margin nearly unchanged. Versus the same quarter a year ago, revenue and gross profit both increased, and gross margin improved.
- The relationship among revenue, cost of revenue, and gross profit shows that cost of revenue remained stable quarter over quarter, so the slight revenue decline drove a proportional drop in gross profit and a nearly flat margin. Year over year, revenue grew faster than cost of revenue, supporting the gross margin improvement.
- Compared to the preceding quarter, gross margin was stable (69.5% versus 69.6%). Compared to the same quarter one year earlier, gross margin improved (69.5% versus 68.8%).
Gross margin snapshot
The selected quarter's reported revenue, gross profit, direct costs, and margin comparisons.
Gross margin
69.5%
Gross profit
$3.6B
Revenue
$5.2B
Cost of revenue
$1.6B
Quarter-over-quarter change
-0.1 pts
Year-over-year change
+0.6 pts
Quarterly gross margin trend
A four-quarter view of the revenue and direct-cost bridge behind gross margin.
| Period | Revenue | Gross profit | Cost of revenue | Gross margin |
|---|---|---|---|---|
| Jun 30, 2025 | $5.1B | $3.4B | $1.6B | 67.7% |
| Sep 30, 2025 | $5.1B | $3.5B | $1.5B | 69.9% |
| Dec 31, 2025 | $5.3B | $3.7B | $1.6B | 69.6% |
| Mar 31, 2026 | $5.2B | $3.6B | $1.6B | 69.5% |
Quarterly comparisons
Compare the selected margin with the preceding quarter and the same fiscal quarter one year earlier.
Previous-quarter change
Dec 31, 2025
-0.1 pts
Year-over-year change
Mar 31, 2025
+0.6 pts
What the margin says
Filing-constrained interpretation of margin direction, comparisons, and what to monitor next.
The relationship among revenue, cost of revenue, and gross profit shows that cost of revenue remained stable quarter over quarter, so the slight revenue decline drove a proportional drop in gross profit and a nearly flat margin. Year over year, revenue grew faster than cost of revenue, supporting the gross margin improvement.
Compared to the preceding quarter, gross margin was stable (69.5% versus 69.6%). Compared to the same quarter one year earlier, gross margin improved (69.5% versus 68.8%).
Monitor whether cost of revenue, which was unchanged sequentially despite lower revenue, begins to rise in future quarters.
Peer context
Latest available gross margins for related public companies.
| Company | Gross margin |
|---|---|
| Boston Scientific Corporation (BSX) | 69.5% |